Clinical Accelerator fosters a collaborative environment that enables scientists to advance their most ambitious clinical and translational research ideas, and accelerates studies that one group or company could not do alone.
*Immunotherapy results may vary from patient to patient.
Cancer Research Institute | National Headquarters
29 Broadway, Floor 4 | New York, NY 10006-3111
(800) 992-2623(212) 832-9376Staff Directory
Patients with advanced hepatocellular carcinoma (HCC), the most common form of liver cancer, can now receive PD-1 immunotherapy for treatment.
Sixteen Team CRI runners ran the 26.2 mile 2018 TCS New York City Marathon and raised an impressive total of $110,000.